Statins blunt HAART-induced CD4 T-cell gains but have no long-term effect on virologic response to HAART

Journal of the International Association of Physicians in AIDS Care

Volumn 6, Issue 3, 2007, Pages 198-202

  Rodriguez, Benigno ^a   Valdez, Hernan ^a,c   Mijch, Anne ^b   Watson, Kerrie ^b   Lederman, Michael M ^a   McComsey, Grace A ^a   Loupa, Chariclia V ^a,d   Woolley, Ian ^b  

^a Foley Building ^*  (United States)

^b ALFRED HOSPITAL   (Australia)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d AMALIA FLEMING GENERAL HOSPITAL   (Greece)

Author keywords

CD4 T cell count; hyperlipidemia; immune reconstitution; statins

Indexed keywords

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; TIME; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; TIME; VIRAL LOAD;

EID: 38949182332     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109707300684     Document Type: Article

References (26)

1. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001 ; 135 (1). 17-26. (Pubitemid 32619279)
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 ; 338 (13). 853-860. (Pubitemid 28135961)
3. Saves M., Raffi F., Capeau J., et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002 ; 34 (10). 1396-1405. (Pubitemid 34507951)
4. Mulligan K., Grunfeld C., Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000 ; 23 (1). 35-43. (Pubitemid 30123263)
5. Fontas E., van Leth F., Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles ? J Infect Dis. 2004 ; 189 (6). 1056-1074. (Pubitemid 38373099)
6. Romeu J., Sirera G., Rego MJ Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy ; September 1999 ; San Francisco, CA.
7. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 ; 37 (5). 613-627. (Pubitemid 37100800)
8. Wiklund O., Mattsson-Hulten L., Hurt-Camejo E., Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med. 2002 ; 251 (4). 338-347. (Pubitemid 34592108)
9. Mach F. Immunosuppressive effects of statins. Atheroscler Suppl. 2002 ; 3 (1). 17-20.
10. Holm T., Andreassen AK, Ueland T., et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol. 2001 ; 87 (6). 815-818, A9. (Pubitemid 32209111)
11. Rosenson RS, Tangney CC, Casey LC Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999 ; 353 (9157). 983-984. (Pubitemid 29132615)
12. Solheim S., Seljeflot I., Arnesen H., Eritsland J., Eikvar L. Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis. 2001 ; 157 (2). 411-415. (Pubitemid 32710020)
13. Weitz-Schmidt G., Welzenbach K., Brinkmann V., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001 ; 7 (6). 687-692. (Pubitemid 32588024)
14. Benner JS, Glynn RJ, Mogun H., Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002 ; 288 (4). 455-461. (Pubitemid 34787476)
15. Narayan S., Hawley N., Giguere P., Badley AD Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin Trials. 2003 ; 4 (3). 164-169. (Pubitemid 36748621)
16. Iloeje UH, Yuan Y., Moorman AC, Wood KC, Holmberg SD Concurrent statin therapy blunts CD4 T cell gain in combination antiretroviral therapy (CART) treated HIV-infected patients. In: 6th International Workshop on Adverse Drug Reactions and Lipodistrophy in HIV, Abstract 69 ; 2004 October; Washington, DC: Antivir Ther ; 2004. p. L41.
17. Valdez H., Connick E., Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS. 2002 ; 16 (14). 1859-1866.
18. Bonnet F., Balestre E., Thiebaut R., et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med. 2004 ; 5 (3). 133-139. (Pubitemid 38765278)
19. Negredo E., Molto J., Burger D., et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS. 2004 ; 18 (3). 459-463. (Pubitemid 38365873)
20. Barrios A., Negredo E., Rendon A., et al. Paradoxical CD4 T-cell decline in patients with complete virus suppression under tenofovir plus didanosine combinations. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract H-1132 ; 2004 ; Washington, DC ; 2004.
21. Youssef S., Stuve O., Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002 ; 420 (6911). 78-84. (Pubitemid 35291443)
22. Olsson AG, Schwartz GG, Jonasson L., Linderfalk C. Are early clinical effects of cholesterol lowering mediated through effects on inflammation? Acta Physiol Scand. 2002 ; 176 (2). 147-150. (Pubitemid 35216290)
23. Jonasson L., Linderfalk C., Olsson J., Wikby A., Olsson AG Systemic T-cell activation in stable angina pectoris. Am J Cardiol. 2002 ; 89 (6). 754-756. (Pubitemid 34230573)
24. Sarria A., Moreno LA, Mur M., et al. Lymphocyte T subset counts in children with elevated low-density lipoprotein cholesterol levels. Atherosclerosis. 1995 ; 117 (1). 119-123.
25. Muldoon MF, Marsland A., Flory JD, Rabin BS, Whiteside TL, Manuck SB Immune system differences in men with hypo- or hypercholesterolemia. Clin Immunol Immunopathol. 1997 ; 84 (2). 145-149. (Pubitemid 27353465)
26. de Baar MP, Smolders Kgm, Buitelaar M., Dekker JT, Klerkx AH Do statins enhance HIV Do statins enhance HIV-therapy induced mitochondrial toxicity ? In: 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Abstract 37 ; 2004 2004 ; Washington, DC: Antivir Ther ; 2004. p. L25.